Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
The Burden of Prostate Cancer in North Africa and Middle East, 1990–2019: Findings From the Global Burden of Disease Study Publisher



Abbasikangevari M1 ; Moghaddam SS1 ; Ghamari SH1 ; Azangoukhyavy M1 ; Malekpour MR1 ; Rezaei N1, 2 ; Rezaei N1, 2 ; Kolahi AA3 ; Amini E1, 4 ; Mokdad AH5, 6 ; Jamshidi H7 ; Naghavi M5 ; Larijani B2 ; Farzadfar F1, 2 Show All Authors
Authors
  1. Abbasikangevari M1
  2. Moghaddam SS1
  3. Ghamari SH1
  4. Azangoukhyavy M1
  5. Malekpour MR1
  6. Rezaei N1, 2
  7. Rezaei N1, 2
  8. Kolahi AA3
  9. Amini E1, 4
  10. Mokdad AH5, 6
  11. Jamshidi H7
  12. Naghavi M5
  13. Larijani B2
  14. Farzadfar F1, 2
  15. Khanali J3
  16. Rashidi MM3, 115
  17. Ahmadi A8, 37
  18. Ahmadi S9
  19. Gholamalizadeh M10
  20. Hajmirzaian A11, 12
  21. Mafi AR13
  22. Nejadghaderi SA14
  23. Azadnajafabad S15
  24. Maroufi SF15
  25. Mohammadi E15, 26
  26. Momtazmanesh S15
  27. Shobeiri P15
  28. Abbasi B16
  29. Akhavizadegan H17
  30. Alimohamadi Y18, 46
  31. Hafezinejad N19, 86
  32. Karimi A19
  33. Nowroozi A19
  34. Malekzadeh R20, 76
  35. Sepanlou SG20, 76
  36. Nasab EM21
  37. Shirkoohi R22
  38. Vakhshiteh F23
  39. Yazdanpanah JF24
  40. Zahir M25, 133
  41. Abidi H27
  42. Zoladl M28
  43. Abugharbieh E29
  44. Afzal MS30
  45. Saqib N31, 124
  46. Ahmad AR32, 33
  47. Ahmad S34
  48. Mohammadianhafshejani A35
  49. Bagheri N36
  50. Ahmed H37
  51. Akbarzadehkhiavi M38
  52. Hosseini MS39
  53. Mamaghani AJ40, 92
  54. Mahmoodpoor A41
  55. Hamad HA42
  56. Sathian B43, 125
  57. Alhalaiqa FAN44, 45
  58. Batiha AMM44
  59. Arabloo J47
  60. Kabir A48
  61. Noori M49, 50
  62. Tiyuri A49, 50, 56
  63. Aljunid SM51, 52
  64. Almidani O53, 54
  65. Arabzozani M55
  66. Athari SS57
  67. Jafari AA58
  68. Mirmoeeni S58
  69. Baghcheghi N59
  70. Koohestani HR60
  71. Bagherieh S61
  72. Fatehizadeh A62
  73. Bhagavathula AS63, 64
  74. Bijani A65
  75. Butt NS66
  76. Malik AA67, 106
  77. Natto ZS68, 109
  78. Soltani RDC69
  79. Golitaleb M70
  80. Moradzadeh R71
  81. Zamanian M71
  82. Daryani A72
  83. Rafiei A73
  84. Dianatinasab M74, 75
  85. Shahabi S77
  86. Sayed IE78
  87. Elhadi M79
  88. Fereidoonnezhad M80
  89. Foroutan M81
  90. Goleij P82
  91. Gubari MIM83
  92. Sheikhbahaei S84
  93. Hamidi S85
  94. Haque S86
  95. Hayat K87, 88
  96. Househ M89
  97. Jamshidi E90, 91
  98. Joukar F93, 94
  99. Mansourghanaei F93, 94
  100. Naghipour M93, 95
  101. Kalhor R96, 97
  102. Khader YS98
  103. Kiani B99
  104. Sahebkar A100, 101
  105. Livani S102
  106. Mohammadi S103
  107. Madadizadeh F104
  108. Majidzadeha K105
  109. Mohammad Y107
  110. Moraga P108
  111. Okatialiabad H110
  112. Pakzad R111
  113. Piracha ZZ112
  114. Pottoo FH113
  115. Rahmanian V114
  116. Razeghinia MS116, 118
  117. Sahebazzamani M117, 120
  118. Rezaeian M119
  119. Saeed U121, 122
  120. Samy AM123
  121. Shaikh MA126
  122. Suleman M127, 128
  123. Ullah I129, 130
  124. Tahbaz SV131, 132
  125. Yahyazadeh SH131
  126. Yuce D134
  127. Zare I135

Source: Frontiers in Oncology Published:2022


Abstract

Background: Prostate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years (DALYs), and the burden attributable to smoking during 1990-2019 in North Africa and Middle East using data of Global Burden of Diseases (GBD) Study 2019. Methods: This study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment. Results: The age-standardized rates (95% UI) of PCa incidence, prevalence, and death in 2019 were 23.7 (18.5-27.9), 161.1 (126.6-187.6), and 11.7 (9.4-13.9) per 100,000 population. While PCa incidence and prevalence increased by 77% and 144% during 1990-2019, respectively, the death rate stagnated. Of the 397% increase in PCa new cases, 234% was due to a rise in the age-specific incidence rate, 79% due to population growth, and 84% due to population aging. The YLLs, YLDs, and DALYs of PCa increased by 2% (-11.8-23.1), 108% (75.5-155.1), and 6% (-8.9-28.1). The death rate and DALYs rate attributable to smoking have decreased 12% and 10%, respectively. The DALYs rate attributable to smoking was 37.4 (15.9-67.8) in Lebanon and 5.9 (2.5-10.6) in Saudi Arabia, which were the highest and lowest in the region, respectively. Conclusions: The PCa incidence and prevalence rates increased during 1990-2019; however, the death rate stagnated. The increase in the incidence was mostly due to the rise in the age-specific incidence rate, rather than population growth or aging. The burden of PCa attributable to smoking has decreased in the past 30 years. Copyright © 2022 Abbasi-Kangevari, Saeedi Moghaddam, Ghamari, Azangou-Khyavy, Malekpour, Rezaei, Rezaei, Kolahi, GBD 2019 NAME Prostate Cancer Collaborators, Amini, Mokdad, Jamshidi, Naghavi, Larijani and Farzadfar.
Other Related Docs